

1

2 **Protein haploinsufficiency drivers identify *MYBPC3*** 3 **mutations that cause hypertrophic cardiomyopathy**

4 Carmen Suay-Corredera^{1,¶}, Maria Rosaria Pricolo^{1,2,¶}, Elías Herrero-Galán¹, Diana Velázquez-
5 Carreras¹, David Sánchez-Ortiz¹, Diego García-Giustiniani³, Javier Delgado⁴, Juan José Galano-
6 Frutos^{5,6}, Helena García-Cebollada^{5,6}, Silvia Vilches^{7,8}, Fernando Domínguez^{1,7,8,9}, María
7 Sabater Molina^{8,10}, Roberto Barriales-Villa^{9,11}, Giulia Frisso^{2,12}, Javier Sancho^{5,6,13}, Luis
8 Serrano^{4,14,15}, Pablo García-Pavía^{7,8,9,16}, Lorenzo Monserrat³, Jorge Alegre-Cebollada^{1,*}

9

10 ¹ Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

11 ² Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico
12 II, Napoli, Italy

13 ³ Health in Code, A Coruña, Spain

14 ⁴ EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRG), The
15 Barcelona Institute of Science and Technology, Barcelona, Spain

16 ⁵ Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias,
17 Universidad de Zaragoza, Zaragoza, Spain

18 ⁶ Biocomputation and Complex Systems Physics Institute (BIFI). Joint Units BIFI-IQFR (CSIC)
19 and GBs-CSIC, Universidad de Zaragoza, Zaragoza, Spain

20 ⁷ Heart Failure and Inherited Cardiac Diseases Unit. Department of Cardiology. Hospital
21 Universitario Puerta de Hierro, Madrid, Spain

22 ⁸ European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart
23 (ERN GUARD-HEART), <http://guardheart.ern-net.eu/>

24 ⁹ Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV),
25 Madrid, Spain

26 ¹⁰ Hospital C. Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain

27 ¹¹ Unidad de Cardiopatías Familiares, Instituto de Investigación Biomédica de A Coruña
28 (INIBIC), Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde
29 (SERGAS), Universidade da Coruña, A Coruña, Spain

30 ¹² CEINGE Biotecnologie Avanzate, scarl, Naples, Italy

31 ¹³ Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain

32 ¹⁴ Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

33 ¹⁵ Universitat Pompeu Fabra (UPF), Barcelona, Spain

34 ¹⁶ Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain

35 [¶] These authors contributed equally to this work

36 ^{*} To whom correspondence should be addressed: jalegre@cnic.es (@AlegreCebollada)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **ABSTRACT**

2 Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Mutations
3 in *MYBPC3*, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are a leading cause
4 of HCM. However, it remains challenging to define whether specific gene variants found in
5 patients are pathogenic or not, limiting the reach of cardiovascular genetics in the management of
6 HCM. Here, we have examined cMyBP-C haploinsufficiency drivers in 68 clinically annotated
7 non-truncating variants of *MYBPC3*. We find that 45% of the pathogenic variants show alterations
8 in RNA splicing or protein stability, which can be linked to pathogenicity with 100% and 94%
9 specificity, respectively. Relevant for variant annotation, we uncover that 9% of non-truncating
10 variants of *MYBPC3* currently classified as of uncertain significance induce one of these
11 molecular phenotypes. We propose that alteration of RNA splicing or protein stability caused by
12 *MYBPC3* variants provide strong evidence of their pathogenicity, leading to improved clinical
13 management of HCM patients and their families.

14

1 INTRODUCTION

2 Hypertrophic cardiomyopathy (HCM) is the most frequent inherited cardiac muscle disease, with
3 an estimated global prevalence of at least 0.5%¹⁻³. HCM is a frequent cause of sudden cardiac
4 death in the young, and can result in several cardiovascular complications including heart failure
5 and thromboembolism¹. Identification of HCM-causative mutations has revolutionized clinical
6 management of patients and their families. Nowadays, genetic testing can confirm a clinical
7 suspicion, help differential diagnosis, and is at the basis of family cascade screening allowing
8 reproductive and professional counselling. However, similar to many other genetic conditions, a
9 fundamental limitation stems from the rarity of HCM genetic variants^{4,5}. For many of them, the
10 number of individuals who can be studied is scarce. As a result, detailed segregation studies are
11 seldom possible, leaving numerous variants classified as of uncertain significance (VUS). This
12 situation has motivated efforts to assess pathogenicity of VUS using functional and population
13 genetics approaches⁶⁻¹⁰.

14
15 Mutations in *MYBPC3*, the gene coding for cardiac myosin-binding protein C (cMyBP-C), are a
16 leading cause of HCM (**Figure 1a**)^{4,11,12}. Most well-established pathogenic variants in *MYBPC3*
17 are frameshift, nonsense or conserved RNA splice site mutations that result in truncated
18 polypeptides, which are more prone to degradation leading to lower total cMyBP-C protein levels
19 (haploinsufficiency)^{13,14}. Indeed, cMyBP-C haploinsufficiency results by itself in the
20 development of HCM (**Figure 1a, middle**)¹⁴⁻¹⁷. Intriguingly, up to 15% of familial HCM cases
21 can be caused by mutations in exonic regions of *MYBPC3* that do not lead to truncations (**Figure**
22 **1a, right**)^{3,4,14,16,18}, including the most common pathogenic mutation in HCM (c.1504C>T,
23 p.R502W)¹³. As of April 2020, ClinVar lists 708 missense and synonymous variants in *MYBPC3*
24 potentially linked to HCM.

25 Non-truncating *MYBPC3* variants currently pose a major challenge to genetic diagnosis in HCM.
26 Despite recent encouraging developments, for most variants it remains impossible to assign
27 pathogenicity just from their location in the gene or the nature of specific amino acid changes¹⁰.
28 Interestingly, both truncating and non-truncating mutations lead to similar HCM clinical
29 manifestation^{19,20}, suggesting that pathogenicity in non-truncating mutations could also result
30 from cMyBP-C haploinsufficiency. Two mechanisms emerge as the most common inducers of
31 protein haploinsufficiency by putative non-truncating variants in monogenic diseases, i.e. defects
32 in RNA splicing that result in the appearance of premature stop codons²¹, and reduction of protein
33 stability²². Both haploinsufficiency drivers have been reported before in *MYBPC3* variants linked
34 to HCM^{7,8,16,18,23-26}. However, the association of these molecular features to disease remains
35 unknown due to the absence of systematic comparison with non-pathogenic variants. For instance,
36 mild changes in splicing may be better tolerated than full native splicing abrogation by a
37 conserved splice site mutation¹⁸. Ito *et al.* have shown that putative non-truncating *MYBPC3*
38 variants appearing in cardiomyopathy gene databases lead to more frequent RNA splicing
39 alteration than variants in control databases, although interpretation of results is complicated by
40 the presence of HCM mutation carriers in the general population^{7,27}.

41 Here, we have examined cMyBP-C haploinsufficiency drivers in missense and synonymous
42 variants in *MYBPC3* in the quest of molecular features that can identify pathogenicity. Our
43 strategy builds on robust pathogenicity assignment, which limits the number of variants that can
44 be analyzed, but has the potential to identify and quantify pathogenic molecular phenotypes with
45 high confidence. We propose that easily testable, mutation-induced RNA splicing alteration and
46 extensive protein destabilization provide strong evidence of pathogenicity of close to 10% of
47 putative non-truncating *MYBPC3* variants currently considered as of uncertain significance.




Figure 1. cMyBP-C haploinsufficiency drivers induced by pathogenic and non-pathogenic variants of MYBPC3. (a) *Left*: scheme of the location of cMyBP-C (in yellow) in the sarcomere. *Middle*: Most HCM-causing mutations in MYBPC3 lead to truncated polypeptides and protein haploinsufficiency. *Right*: The remaining mutations are non-truncating and result in full-length mutant proteins (mutated domain is represented in red). (b) Workflow to identify cMyBP-C haploinsufficiency drivers in pathogenic and non-pathogenic variants of MYBPC3. The number of variants that are positive for predicted alterations of RNA splicing or protein stability are indicated, together with the outcomes of experimental validation (the protein stability of 6 variants per group were also screened, shown between parentheses). Pathogenic mutations are indicated in pink and non-pathogenic variants, in green. (c) Prediction of alterations in RNA splicing. Each bar corresponds to a single variant and is colored according to the predicted effect. Predictions for pathogenic mutations are shown in the upper half of the panel, while results for non-pathogenic variants appear in the lower half. Blue triangles indicate exon-exon boundaries. Organization of domains in cMyBP-C is indicated at the bottom of the panel. (d) Prediction of alterations of protein stability. Each bar corresponds to a single variant and is colored according to the pathogenicity of the variant (pathogenic, pink; non-pathogenic, green). The dotted lines mark the highest destabilizing change in $\Delta\Delta G$ detected for a non-pathogenic variant (green), and the lowest destabilization of a pathogenic mutation over the non-pathogenic threshold (pink).

1 RESULTS

2 A database of clinically curated variants of *MYBPC3*

3 We built a database containing 44 pathogenic and 24 non-pathogenic putative synonymous and
4 missense *MYBPC3* variants covering the entire coding sequence of the gene (see Methods,
5 **Supplementary File S1**). These variants were selected because they have unambiguous
6 pathogenicity assignment based only on cosegregation and epidemiological criteria validated by
7 the American College of Medical Genetics (ACMG) ²⁸. We verified that clinical information
8 publicly available in ClinVar is in excellent agreement with our pathogenicity assignment
9 (**Supplementary Figure S1**). In addition, all the non-pathogenic variants have minor allele
10 frequency (MAF) $>10^{-4}$, while that of the pathogenic variants is $<10^{-4}$. This threshold has been
11 proposed before on the basis of HCM prevalence in the general population ¹³. After configuration
12 of the database of variants, we investigated whether alteration of RNA splicing and protein
13 stability are specific to pathogenic mutations, under the premise that molecular features related to
14 HCM should not appear in non-pathogenic variants. We first triaged variants using bioinformatics
15 predictors and then validated positive hits experimentally (**Figures 1b-d,2,3**).

16 Alteration of RNA splicing by pathogenic mutations

17 RNA splicing is the process by which non-coding introns are removed from precursor mRNA,
18 leading to exon-only-containing mature mRNA. Splicing involves recognition of specific
19 sequences, particularly the strictly conserved two first (donor site) and last (acceptor site)
20 nucleotides of introns. Mutations in these sequences impair canonical splicing, resulting in
21 alternative mRNAs that contain premature stop codons, or lead to insertion/deletions in the
22 polypeptide ²⁹. Indeed, mutations in *MYBPC3* that affect these conserved splicing sites are usually
23 considered to lead to a null allele and are classified as pathogenic ¹³. However, the correct
24 functioning of the splicing machinery also involves recognition of sequence features in the exons,
25 particularly in regions close to intron-exon boundaries. As a consequence, mutations in exonic
26 sequences of *MYBPC3* traditionally classified as missense can result in alterations of RNA
27 splicing that lead to truncated polypeptides ^{7,8,18,30}. Indeed, we find that 6 pathogenic mutations in
28 our database are predicted *in silico* to induce splicing site losses (**Figure 1c, Table 1**). The 6
29 mutations target the first or last nucleotide of an exon (**Supplementary Note S1**). Predictions also
30 identify 7 pathogenic mutations that can lead to activation of new splicing sites. In contrast, all
31 non-pathogenic variants target nucleotides outside exon-exon boundaries and none of them is
32 predicted to cause loss of native splicing sites. For two non-pathogenic variants, the appearance
33 of a new splicing site is suggested (**Figure 1c, Table 1, Supplementary Note S1**).

34 To validate predicted alterations in RNA splicing, we mined data available in the literature and
35 analyzed RNA splicing in those cases for which there was no reported experimental information.
36 RNA splicing of the *MYBPC3* transcript is best studied from myocardial samples; however, the
37 scarcity of genotyped myocardium has limited analysis to a few variants ^{8,16,18}. We have employed
38 two alternative, more accessible strategies whose results are so far in excellent agreement with
39 experiments using myocardial samples, i.e. analysis of mRNA from the leukocyte fraction of
40 peripheral blood from variant carriers ³⁰⁻³⁵, and *in vitro* experiments using mini-gene constructs
41 ^{7,34,36} (**Supplementary Table S1**). In both cases, isolated mRNA was amplified by RT-PCR using
42 specific pairs of primers, and results were analyzed by electrophoresis and Sanger sequencing
43 (**Figure 2, Supplementary File S2**).

44 In **Figure 2a-g**, we show results from amplification of the exon15-exon21 region using mRNA
45 obtained from blood samples that carry different *MYBPC3* variants. If splicing is correct,
46 amplification results in a fragment of 692 bp, as shown for the wild-type (WT) individual (**Figure**




Figure 2. Experimental characterization of RNA splicing alteration induced by *MYBPC3* variants. (a) Location of two pathogenic mutations in the exon 17 of *MYBPC3* that are predicted to induce alterations of splicing. The positions of donor, *d*, and acceptor, *a*, splicing sites are indicated. (b) Experimental determination of RNA splicing by RT-PCR analysis of mRNA isolated from peripheral blood of carriers. CTRL+, mRNA obtained from healthy myocardium. CTRL-, mRNA isolated from HeLa cells, which do not express *MYBPC3*. The theoretical size of the amplified region if splicing is correct is 692 bp. In some samples, including CTRL -, a non-specific band is detected at a mobility between 300–400 bp. We could not identify the origin of this band. (c) Prediction of RNA splicing alteration for mutant c.1624G>C (p.E542Q). (d) Sanger sequencing result for c.1624G>C (p.E542Q) amplification product, which identifies the skipping of exon 17. The sequence resulting from the predicted change in splicing due to mutation c.1624G>C is shown in the blue box. Please note that the sequences of exons 17 and 18 are detected from the last nucleotide of exon 16, as expected from the presence of wild-type and mutated alleles in the heterozygous donor. (e) Sanger sequencing result for the WT amplification product showing normal splicing. (f) Prediction of RNA splicing alteration for mutant c.1505G>A (p.R502Q). (g) Sanger sequencing result for c.1505G>A (p.R502Q). (h) Mini-gene strategy to study splicing defects in non-pathogenic variant c.492C>T (p.G164G), which is located in exon 4 of *MYBPC3*. (i) Results from RT-PCR amplification of mRNA. CTRL- is a non-transfected control. (j,k) Prediction of RNA splicing alteration and Sanger sequencing result for variant c.492C>T (p.G164G). In panels (b) and (i), we use “n” and “s” to indicate bands corresponding to native splicing, or to skipping of exons, respectively. M corresponds to 1Kb plus DNA ladder (Invitrogen) and base pairs are indicated. See **Supplementary File S2** for experimental details.

- 1 **2b).** We observe that mutation c.1624G>C (p.E542Q) leads to a higher-electrophoretic-mobility
- 2 band at 500 bp, marking skipping of exon 17, in agreement with predictions that native donor site
- 3 is perturbed by the mutation (**Figure 2c,d,e**). In contrast, the prediction that mutation c.1505G>A
- 4 (p.R502Q) causes an acceptor site gain was not validated, as splicing proceeded as for the WT
- 5 (**Figure 2b,f,g,e**). Equivalent results have been obtained before by others (**Table 1**).

Variant (cDNA)	Variant (Protein)	Pathogenic variant	Predicted splicing alteration	Experimental splicing alteration (myocardium)	Experimental splicing alteration (blood)	Experimental splicing alteration (mini-gene)	Reference
292G>C	E98Q	Yes	DL	-	-	-	Supp. File S2
442G>A	G148R	Yes	AG	-	-	Yes	7
492C>T	G164G	No	DG	-	-	No	Figure 2i
655G>T	V219F	Yes	AL	-	-	Yes	7,36
772G>A	E258K	Yes	DL, AG	Yes (DL)	Yes (DL)	Yes (DL)	7,8,18,37
1505G>A	R502Q	Yes	AG	-	No	No	Figure 2b and 7
1624G>C	E542Q	Yes	DL	Yes	Yes	Yes	Figure 2b and 7,16,18,30,36
2286C>G	V762V	Yes	DG	-	-	No	Supp. Figure S2d
2308G>A	D770N	Yes	DL	Yes	-	-	18
2503C>T	R835C	Yes	DG	-	-	-	Supp. File S2
2834G>A	R945Q	Yes	AG	-	-	-	Supp. File S2
3106C>T	R1036C	No	AG	-	-	No	7
3330G>A	M1110I	Yes	DL	-	Yes	-	Supp. Figure S2e
3790T>C	C1264R	Yes	DG	-	-	-	Supp. File S2

Table 1. Experimental validation of predicted alterations of RNA splicing in pathogenic and non-pathogenic variants of *MYBPC3*. DL: donor loss; DG: donor gain; AL: acceptor loss; AG: acceptor gain. Validation of predictions using myocardial, blood or mini-gene experiments samples are indicated. Mutants c.292G>C, c.2503C>T, c.2834G>A and c.3790T>C could not be studied.

1 In **Figure 2h-k**, we present the results of a mini-gene strategy to test whether the non-pathogenic
2 variant c.492C>T (p.G164G) induces the appearance of a new donor site. RT-PCR amplification
3 shows leads to two bands both in the WT and the mutant sample (**Figure 2i**). The band at 850 bp
4 corresponds to the skipping of the *MYBPC3* insert, a scenario which is not uncommon in mini-
5 gene assays. The band at 1100 bp results from the correct inclusion of exons 4 and 5 of *MYBPC3*
6 in the mini-gene transcript, which was further verified by Sanger sequencing (**Figure 2k**). No
7 other band was amplified in the c.492C>T sample. Hence, the prediction in **Figure 2j** of a new
8 splicing site for variant c.492C>T (p.G164G) was not validated experimentally.

9 We followed equivalent strategies to examine experimentally all predictions of altered RNA
10 splicing. In total, we were able to collect results for 11 out of the 15 predicted alterations (**Table**
11 **1**). For the 4 remaining variants, we could not recruit carriers and the mini-gene assays did not
12 recapitulate native splicing in WT sequences (**Supplementary Figure S3**). RNA splicing
13 alterations leading to premature stop codons could be confirmed experimentally in 6/8 pathogenic
14 mutations (**Figure 1b, Supplementary Table S2**). Validation rate in this set of variants was 5/5
15 for splicing site losses and 1/6 for splicing site gains. Importantly, none of the predicted alterations
16 of splicing in non-pathogenic variants was confirmed experimentally (**Table 1**). Hence, our
17 results indicate that prediction of RNA splicing alterations and subsequent experimental
18 validation captures at least 14% of the pathogenic mutations with 100% specificity ($p = 0.037$,
19 Fisher's exact test, **Figure 1b, Table 1, Supplementary Note S2**).

20 Pathogenic mutations induce extensive protein destabilization

21 A reduction in protein stability leads to more frequent unfolding, which can result in degradation-
22 sensitive polypeptides and reduced total protein levels^{22,38}. To analyze protein destabilization
23 induced by the variants in our database, we used FoldX³⁹. This software can predict protein




Figure 3. Experimental characterization of protein destabilization induced by MYBPC3 variants. (a) cMyBP-C encompasses 11 domains. To analyze structural destabilization induced by mutations, we produced recombinant versions of WT and mutant domains in *E. coli* (domains not colored could not be expressed). (b) Representations of domains C1 (pdb: 3cx2) and C5 (pdb: 1gxe), highlighting positions targeted by 2 pathogenic mutations (in red) and by 1 non-pathogenic variant (in green). Panel was produced with Chimera⁴⁰. (c) CD spectra (given as mean residue ellipticity, MRE) obtained for C5 WT (black), and C5-P645L (red) domains. (d) CD spectra obtained for C1 WT (black), and C1-R177H (green) domains. (e) Thermal denaturation curves of C1 WT (black), and C1-R177H (green) obtained by tracking the CD signal at 205 nm. The temperature at the midpoint of the transition, T_m , is obtained from sigmoidal fits to denaturation curves considering a two-state unfolding process. (f) T_m for WT cMyBP-C domains. (g) Change in T_m induced by pathogenic (red) and non-pathogenic (green) variants. Plot also indicates mutant domains that could not be expressed or that resulted in altered CD spectrum at 25°C. The raw data for all mutants are presented in **Supplementary Figures S4 and S5**. Position of cMyBP-C domains is indicated at the top of the panel.

1 destabilization if the high-resolution 3D structures of targeted domains are known. Hence, we
 2 examined the stability of the variants affecting domains C0, C1, C2, C3, and C5 of cMyBP-C, for
 3 which high-resolution structures are available (PDB codes: 2k1m, 3cx2, 1pd6, 2mq0, 1gxe,
 4 respectively). We found that the average predicted destabilization induced by pathogenic
 5 mutations is higher than for non-pathogenic variants ($\Delta\Delta G = 1.8 \pm 0.6$ vs 0.7 ± 0.4 kcal/mol, errors
 6 are SEM, $p = 0.049$, one-sided Student's t-test). Closer inspection of the data shows that
 7 pathogenic mutations p.P187R, p.V471E, p.P645L are predicted to induce extensive reduction of
 8 stability, well above the highest destabilization estimated for non-pathogenic variants (**Figure 1d**;
 9 **Supplementary File S1**). The distribution of $\Delta\Delta G$ values for the rest of pathogenic mutants
 10 appears indistinguishable from that of non-pathogenic variants (**Figure 1d**).

11

12 To validate predictions of extensive domain destabilization induced by pathogenic mutations, we
 13 examined experimentally the stability of 18 mutated domains throughout the sequence of cMyBP-




Figure 4. Landscape of molecular phenotypes induced by putative non-truncating pathogenic mutations in *MYBPC3*. For this analysis, we only considered the 27 pathogenic mutations in our database in **Supplementary File S1** for which data on protein stability were available (21 predictions and 6 additional mutations that were studied experimentally in the absence of predictions). Predictions of RNA splicing alteration were available for the 27 pathogenic mutations. All predicted alterations of RNA splicing and protein destabilization were tested experimentally, leading to confirmation of 4 alterations of RNA splicing and 8 highly destabilizing mutations. Our analysis assumes that bioinformatics predictions are able to capture alterations with 100% sensitivity^{7,39}.

1 C (**Figure 3a**). We analyzed the three pathogenic and non-pathogenic variants with the highest
2 predicted destabilization. We also undertook expression of all variants, regardless of
3 pathogenicity, that target domains for which predictions were not available (**Supplementary**
4 **Files S1**, see Methods). We did not study at the protein level variants predicted to cause RNA
5 splicing alterations.
6
7 The expression of mutated domains was induced in *E. coli* and purified domains were analyzed
8 by far-UV circular dichroism (CD) spectroscopy, a technique that reports on protein secondary
9 structure and stability^{41,42}. We found that 7 out of the 9 pathogenic mutants (C1-P187R, C3-
10 V471E, C4-D610N, C10-G1206D, C10-T1237P, C10-Y1251H, C10-L1268P) could not be
11 produced in soluble form in the most favorable expression conditions, suggesting strong
12 destabilization by the mutations (see Methods, **Figure 3b**, **Supplementary File S1**,
13 **Supplementary Figure S4**). Among the pathogenic mutants that could be produced, C5-P645L
14 showed strongly perturbed CD spectrum, indicative of major structural alterations in this mutant
15 (**Figure 3b,c**). The CD spectrum of mutant C4-A627V was more similar to WT, suggesting no
16 major structural alterations in this mutant (**Supplementary Figure S5**). To further characterize
17 the impact of the A627V mutation on domain C4, we tracked the CD signal at increasing
18 temperatures. As the protein domain transitions between the native and the unfolded states, the
19 CD signal varies (**Supplementary Figure S6**) and the temperature at the midpoint of the
20 denaturing transition, or melting temperature (T_m), informs on the thermal stability of the domain
21⁴². We determined that C4-A627V has slightly lower T_m than the WT domain ($\Delta T_m = T_m(\text{WT}) -$
22 $T_m(\text{mutant}) = 5.0$ °C) (**Supplementary Figure S5**). Regarding non-pathogenic variants, 8 out of
23 9 preserve protein structure and stability with maximum ΔT_m values of 4.3 °C (**Figure 3b, d-g**,
24 **Supplementary Figure S5, Supplementary File S1**). These results indicate that limited changes
25 in T_m up to ~5 °C are generally well tolerated and cannot be linked to pathogenicity. There was

Variant (cDNA)	Variant (Protein)	Predicted splicing alteration	Experimental splicing alteration	Reference
39C>T	S13S	DG	-	Supp. File S2
194C>T	T65M	AG	-	Supp. File S2
479G>A	R160Q	AG	No	Supp. Figure S2b
505G>A	G169S	DL, DG	No	Supp. Figure S2c
659A>G	Y220C	DG	No	⁷
1213A>G	M405V	DG	Yes	^{7,36}
1287G>A	A429A	AG	-	Supp. File S2
1309G>A	V437M	DG	-	Supp. File S2
1466A>T	D489V	DG	-	Supp. File S2
2155T>C	C719R	DG	No	Supp. Figure S2d
2217G>A	E739E	AG	No	Supp. Figure S2d
2234A>G	D745G	DG	No	⁷
2249C>T	T750M	AG	No	Supp. Figure S2d
2288A>G	N763S	DG	No	Supp. Figure S2d
2308G>C	D770H	DL	Yes	Supp. Figure S2d

Table 2. Experimental validation of predicted alterations of RNA splicing in *MYBPC3* VUS using mini-genes. DL: donor loss; DG: donor gain; AG: acceptor gain. Five variants could not be studied. We studied experimentally the variants for which no information was available in the literature.

1 only one non-pathogenic variant that could not be produced (C9-R1138H) (**Supplementary**
2 **Figure S4**). Using molecular dynamics simulations, we obtained evidence that most mutant
3 domains that could not be expressed in native form are indeed destabilized (**Supplementary**
4 **Table S3**).

5
6 In summary, our workflow to analyze protein stability was able to capture strong domain
7 destabilization in 18% of the pathogenic mutations. Results indicate that domain destabilization
8 can be linked to pathogenicity with 94% specificity ($p = 0.048$, Fisher's exact test, **Figures 1b,**
9 **3g, Supplementary Note S2**).

10 11 **Prevalence of cMyBP-C haploinsufficiency drivers**

12 Our results in the previous sections show that one third of the pathogenic mutations in our
13 database induce alteration of RNA splicing or extensive protein destabilization. The extent of
14 these cMyBP-C molecular phenotypes among pathogenic mutations is probably higher since
15 bioinformatics predictions are not available for all mutants, particularly in the case of protein
16 destabilization (**Supplementary Figure S7**). Hence, we have analyzed the distribution of
17 cMyBP-C haploinsufficiency drivers in the subset of mutants for which we have information for
18 both RNA splicing and protein stability. This analysis shows that 45% of the mutations induce
19 RNA splicing alteration or protein destabilization, and that reduction in protein stability is two
20 times more frequent than splicing defects (**Figure 4**). Interestingly, the majority of mutations do
21 not induce any of these two molecular phenotypes, as observed before for p.R502W^{16,43}, the most
22 common mutant in HCM¹³.

23
24




Figure 5. Assessment of cMyBP-C haploinsufficiency drivers in MYBPC3 VUS. (a) 73 VUS in ClinVar were screened for alterations of RNA splicing and protein stability (b) Results from predictions of RNA splicing. Blue triangles indicate exon-exon boundaries. Each bar corresponds to a single variant and is colored according to the predicted effect on RNA splicing. (c) Experimental validation of predicted changes Variants which could not be tested by mini-gene assays are colored in light pink (see Table 2). (d) Predicted protein destabilization of the 73 VUS. Each bar corresponds to a single variant and is colored according to the predicted protein destabilization. Reference lines as in Figure 1d. (e) Experimental determination of changes in thermal stability for the 10 VUS with predicted $\Delta\Delta G > 3$ kcal/mol. The green reference line at $\Delta T_m = 5$ °C marks destabilization values that can be found in non-pathogenic variants (Figure 3g), while we consider $\Delta T_m > 10$ °C (pink reference line) a signature of pathogenic mutations (corresponding bars are colored in red, while variants below the 10°C threshold are shown in grey). **Supplementary Figure S8** shows the CD data.

1 Molecular phenotyping of variants of uncertain significance

2 Since defects in RNA splicing and protein destabilization are linked to pathogenicity with close
 3 to 100% specificity, we investigated whether these molecular phenotypes could be used to inform
 4 pathogenicity of putative non-truncating variants currently classified as VUS. To this aim, we
 5 studied the 73 VUS with $MAF < 10^{-4}$ reported in ClinVar that target domains C0, C1, C2, C3 and
 6 C5 of cMyBP-C (Figure 5a, Supplementary File S3). RNA splicing was predicted to be altered
 7 in 14/68 variants in which native splice sites were detected, and a new splicing site was predicted
 8 in one of the 5 remaining variants (Figure 5b, Supplementary File S3). We gathered
 9 experimental information for 10 of them, leading to confirmation of protein-damaging splicing
 10 alterations in 1/2 predicted splice site losses and in 1/9 predicted site gains, both of them leading
 11 to damaging effects at the protein level (Figure 5c, Table 2, Supplementary Table S2).
 12 Regarding protein stability, 10 variants showed higher predicted destabilization than the most

1 destabilized non-pathogenic variant (**Figure 5d**). We verified experimentally extensive domain
2 destabilization in four of them (C1-G155V, C1-G169S, C1-L199P, and C2-V385M, **Figure 5e**,
3 **Supplementary Figure S8**). We considered that $\Delta T_m > 10^\circ\text{C}$ marks major impact in protein
4 stability according to previous screenings of destabilization by single amino acid polymorphisms
5 ⁴⁴. Altogether, we were able to detect alterations of splicing in 2.9% of the VUS for which we had
6 bioinformatics predictions, and up to 3.9% if we consider the expected validation rate of the 5
7 splicing site gain predictions that could not be tested (**Table 2, Supplementary Note S2**). Protein
8 destabilization was apparent in 5.5% of the variants. Hence, both molecular phenotypes in
9 combination provide strong evidence of pathogenicity of 9% of putative missense and
10 synonymous VUS in *MYBPC3*.

11 12 **DISCUSSION**

13 The clinical management of HCM has greatly benefited from the discovery of causative genes
14 over the last two decades ¹. Currently, genetic testing is a Class I recommendation in both the
15 European and American HCM clinical practice guidelines, since identification of pathogenic,
16 actionable genetic variants helps in the clinical care of patients and their families. Thanks to the
17 advent of next-generation DNA sequencing techniques, the number of genetic variants found in
18 HCM patients has increased considerably, leading to new challenges in variant interpretation
19 ^{4,33,45-47}. Many genetic variants are present only in a few patients, limiting the power of
20 cosegregation analyses to assess pathogenicity. Alternatively, molecular and functional deficits
21 linked to disease progression can enable classification of rare pathogenic mutations, as already
22 implemented in the ACMG guidelines ^{28,45,48-50}.

23 Here, we have undertaken molecular phenotyping of variants in *MYBPC3* looking for protein
24 haploinsufficiency drivers that can sustain pathogenicity. Importantly, we have compared well-
25 established pathogenic and non-pathogenic variants, which has allowed us to link molecular
26 properties to pathogenicity. Although our strict clinical criteria result in smaller sample sizes than
27 studies analyzing large genetic databases ⁷, our results show that 45% of putative non-truncating
28 pathogenic mutations in *MYBPC3* significantly and specifically induce alteration of RNA
29 processing or extensive protein destabilization (**Figure 4**). Furthermore, we have identified these
30 pathogenicity drivers in *MYBPC3* variants that are currently classified as VUS (**Figure 5**).

31
32 **Figure 6** summarizes our workflow to assess pathogenicity of *MYBPC3* variants through
33 molecular phenotyping. The first step is to use *in silico* tools to predict alterations in RNA splicing
34 and protein stability. Positive hits are then validated experimentally. Regarding alteration of
35 splicing, we have measured a 14% false positive rate for the prediction of loss of splicing sites,
36 while we have found considerably higher number of false positives for new splicing site
37 prediction, in agreement with previous observations ^{7,33} (**Supplementary Note S2**). Hence,
38 experimental validation of alterations of RNA splicing is a strict requirement to identify true
39 positives, which in the clinical setting can be easily implemented by analyzing the peripheral blood
40 of carriers. We also recommend validation of protein destabilization predictions, since we could
41 only verify extensive protein destabilization in 40% of triaged VUS variants (**Figure 5d,e**).
42 Experimental analysis following negative predictions is discouraged because false negatives are
43 not common in bioinformatics predictions ^{7,39}. Direct experimental testing would only be
44 indicated if algorithms fail to capture native splicing sites, or when there is no high-resolution
45 protein structural information. According to our results, the workflow in **Figure 6** can provide
46 strong evidence of pathogenicity for 9% of the *MYBPC3* missense and synonymous variants
47 currently classified as VUS in ClinVar. As a corollary, considering that alteration of RNA splicing




Figure 6. Flow diagram to characterize clinical impact of putative non-truncating VUS in *MYBPC3*. Following bioinformatics predictions of alteration of RNA splicing or protein stability, experimental validation can result in variant reclassification. n/a: predictions not available. Numbers at the bottom indicate the estimated percentage of reclassifications according to our results.

1 and protein thermal stability are found in 45% of pathogenic mutations (**Figure 4**), we
 2 estimate that 20% of missense and synonymous variants in *MYBPC3* currently classified as VUS
 3 show strong evidence of pathogenicity.

4

5 Our study supports the emerging view that genetic variants that affect RNA splicing are
 6 pathogenic ^{7,8}. Interestingly, these RNA-splicing-altering mutants can be found in exonic and
 7 intronic regions that are far from splice sites if the consequence of the mutation is the activation
 8 of a new splice site (**Tables 1,2**) ^{7,33}. In the clinical setting, evidence of RNA splicing alteration
 9 can lead to variant reclassification following ACMG guidelines ⁸. In this context, false positives
 10 that misclassify non-pathogenic variants as pathogenic are a source of concern ⁵. Some non-
 11 pathogenic variants are found in regions close to splice sites; however, they are not predicted to
 12 alter splicing when compared to pathogenic mutations ⁸. Our data agree with this observation.
 13 (**Supplementary Note S1**). To the best of our knowledge, there is not a single example of a non-
 14 pathogenic variant that has been demonstrated to cause alteration of RNA splicing.

15

16 Importantly, we have identified that more than one third of true pathogenic missense *MYBPC3*
 17 mutations cause extensive protein destabilization. Remarkably, the number of these variants
 18 appears to be higher than the number of exonic mutations affecting RNA splicing (**Figures 4, 5**).
 19 However, there are challenges associated with the functional classification of *MYBPC3* variants

1 following protein stability assessment. First, there is no high-resolution structural information for
2 many cMyBP-C domains, which hampers effective triaging of potentially disruptive mutations.

3
4 A second challenge stems from the validation of protein destabilizing phenotypes using
5 recombinant domains produced in bacteria, which in the case of very damaging mutations can be
6 inherently impossible. Although our interpretation that strong destabilization hampers domain
7 purification is supported by molecular dynamics simulations (**Supplementary Table S3**), lack of
8 stability is not the only reason why recombinant production of mutant domains may fail ⁵¹. In our
9 set of experiments, we could not produce the non-pathogenic the C9 domain carrying variant
10 R1138H. The C9 domain has the lowest T_m value among all domains assayed (42.2°C, **Figure**
11 **3f**). However, C9 is a fibronectin-III type domain, a protein fold whose typical T_m values are well
12 above 50°C ⁵². We speculate that our recombinant C9 domain may not recapitulate native stability
13 and that the impact of minor, non-pathogenic changes in stability may be higher in this context.
14 It is also possible that the native environment of the sarcomere limits the destabilizing effect of
15 the mutation via posttranslational modifications or protein-protein interactions. In this regard,
16 stability analysis of cMyBP-C domains that have interaction partners in the sarcomere may be
17 less specific than in the case of central domains of the protein ⁵³.

18
19 The fact that protein stability is not binary poses a third challenge to protein-destabilization-
20 guided functional classification of variants. We have observed that non-pathogenic variants can
21 cause slight protein destabilization ($\Delta T_m < 5^\circ\text{C}$, **Figure 3g**). We have considered that $\Delta T_m > 10^\circ\text{C}$
22 is a signature of pathogenic protein destabilization taking into account the typical distribution of
23 ΔT_m in unselected single-amino-acid polymorphisms across different proteins ⁴⁴. The confidence
24 of this threshold could be increased by measuring the stability of more non-pathogenic variants.

25
26 Mechanistically, both the alteration of RNA splicing and the destabilization of cMyBP-C domains
27 can lead to reduced cMyBP-C levels, similar to the situation induced by truncating mutations
28 ^{15,24,54,55}. It is remarkable though that many synonymous and pathogenic missense mutations in
29 *MYBPC3* do not alter RNA splicing or protein stability (**Figure 4**). The pathogenicity triggers of
30 those mutations remain unknown. A tempting hypothesis is that some of them induce protein
31 haploinsufficiency by alternative mechanisms, including decreased rates of transcription and
32 translation ⁵⁶⁻⁵⁸, increased recognition by mRNA and protein degradation machineries ^{56,59,60}, and
33 defective incorporation of cMyBP-C in the sarcomere ⁶¹. Alternatively, mutations can lead to
34 altered binding to protein partners ⁶²⁻⁶⁶. Tantalizingly, both scenarios could lead to similarly
35 altered modulation of the super relaxed state of myosin, inducing sarcomere hypercontractility
36 typical of HCM ^{17,67}.

37 In summary, we propose that identification of protein haploinsufficiency drivers in *MYBPC3*
38 variants provides strong evidence of their pathogenicity (PS3 criterion in the ACMG guidelines
39 ²⁸), contributing to the assessment of pathogenicity of putative non-truncating variants of
40 *MYBPC3*. RNA splicing alterations and protein destabilization can be validated using readily
41 available laboratory assays, which addresses the urgent need of methods that assign pathogenicity
42 of genetic variants associated with HCM ^{49,68}. Our strategy increases the number of actionable
43 variants in *MYBPC3*, leading to improved clinical management of HCM families.

44
45
46
47

1 MATERIALS AND METHODS

2 Human samples

3 Human samples were obtained following informed consent of patients according to the guidelines
4 of the Declaration of Helsinki. Research involving humans was authorized by the *Comité de Ética*
5 *de Investigación* of Instituto de Salud Carlos III (PI 39_2017).

7 Selection of genetic variants

8 We retrieved *MYBPC3* variants from the *Health in Code (HIC)-Mutations* database, which
9 includes information about >155,000 individuals obtained from >50,000 articles in the literature,
10 as well as from HIC's own clinical reports. To obtain pathogenicity information from ClinVar, a
11 score was calculated by averaging all available pathogenicity interpretations. With that aim, a
12 scale between 0 and 4 was used for benign (B), likely benign (LB), VUS, likely pathogenic (LP)
13 and pathogenic (P) interpretations. To select VUS in *MYBPC3*, we considered all non-truncating
14 variants associated with hypertrophic cardiomyopathy in ClinVar, excluding those with
15 conflicting interpretations of pathogenicity or showing $MAF > 10^{-4}$. We restricted our analysis to
16 variants targeting domains for which there is high-resolution structural information.

18 Bioinformatics prediction of haploinsufficiency drivers

19 We used Alamut Visual (Interactive Biosoftware) to predict RNA splicing alterations induced by
20 all variants in our pathogenic/non-pathogenic and VUS databases. Alamut implements analyses
21 of four different RNA splicing prediction algorithms (SSF, MaxEnt, NNSPLICE, GeneSplicer).
22 We first determined if at least two of the algorithms identified the canonical splicing site around
23 the mutation site. We then calculated the percent change in splicing score for native sites and for
24 potential new splicing sites. Positive hits result in at least two tools predicting >10% decrease (for
25 native sites) or increase (for new sites) in splicing score, in agreement with published guidelines
26 ⁶⁹. Changes in protein thermodynamic stability were estimated by FoldX. This software estimates
27 changes in free energy ($\Delta\Delta G$) upon mutation from empirically and statistically derived energy
28 functions ³⁹.

30 Analysis of RNA splicing

31 For experimental determination of RNA splicing, we resourced to analysis of blood samples from
32 variant carriers or used engineered mini-gene constructs (**Supplementary File S2**). In the case of
33 blood samples, total RNA was extracted from leukocytes of carriers using Trizol (Thermo Fischer
34 Scientific). RNA retro-transcription was done with random primers by SuperScript™ IV VILO™
35 Master Mix (Thermo Fischer Scientific) and the region of interest was PCR amplified using
36 specific oligos (**Supplementary File S2**). RT-PCR products were purified using the Qiaquick
37 PCR purification Kit (Qiagen) and then Sanger-sequenced when necessary. Correct RNA splicing
38 results in readable electropherograms, obtained for both primers, and whose sequence match the
39 sequence of the canonical cDNA for cMyBP-C. For mini-gene experiments the WT and mutated
40 gDNA fragments were ordered to Integrated DNA Technologies, including at least the exon of
41 interest and the 5' and 3' intronic flanking regions (**Supplementary File S2**). The constructs were
42 cloned into β -globin's intron 2 of pMGene vector ⁷⁰ using KpnI. Alternatively, pMGene vectors
43 including the inserts of interest were ordered to GeneArt Gene Synthesis (from Thermo Fisher
44 Scientific). In both cases, resulting constructs were expressed in monolayers of HEK-293 cells
45 cultured in Dulbecco's modified eagle medium (DMEM, Gibco) supplemented with 10% fetal
46 bovine serum, and 1% penicillin/streptomycin at 37 °C under 5% CO₂. Cells were transiently
47 transfected with 1 μ g of WT or mutated pMGene using FuGENE HD (Promega) according to the
48 manufacturer's protocol. 24-48 hours after transfection, cells were collected and mRNA was

1 extracted and retrotranscribed, and PCR products were purified and sequenced to compare
2 splicing of WT and mutated constructs as above.

3 **Protein expression and purification**

4 The cDNAs coding for the cMyBP-C domains and their mutants were cloned from myocardial
5 RNA, produced by PCR-mutagenesis or acquired commercially to Integrated DNA Technologies.
6 Sequences are available in **Supplementary File S4**. cDNAs were cloned in a custom-modified
7 pQE80L expression plasmid (Qiagen) using BamHI and BglII enzymes. Final expression
8 plasmids were verified by Sanger sequencing. Domains were expressed in *E. coli* BLR(DE3).
9 Cultures at $OD_{600} = 0.6-1$ were induced with isopropyl β -D-1-thiogalactopyranoside (specific
10 conditions in **Supplementary Files S1, S3 and S4**). In general, we found that expression at lower
11 concentrations of IPTG and temperature $\leq 25^\circ\text{C}$ resulted in better yield of purification of
12 challenging-to-express domains, so these conditions were preferred for the expression of mutant
13 domains. Purification of His-tagged domains was achieved by metal affinity and gel filtration
14 chromatographies ⁷¹. WT domains C6 and C8 were refractory to recombinant expression (data
15 not shown), so variants targeting these domains could not be analyzed. Proteins were eluted from
16 the final size-exclusion chromatography in 20 mM NaPi, pH 6.5 and 63.6 mM NaCl. Proteins
17 were stored at 4°C . Purity of the preparations was evaluated by SDS-PAGE (**Supplementary**
18 **Figure S4**).

19 **Circular dichroism**

20 CD spectra were collected using a Jasco J-810 spectropolarimeter. Purified proteins were tested
21 in 20 mM NaPi, pH 6.5 and 63.6 mM NaCl at protein concentrations ranging from 0.1 to 0.5
22 mg/mL in 0.1-cm-pathlength quartz cuvettes. Protein concentration was obtained from A_{280}
23 values using theoretical extinction coefficients (**Supplementary Files S1, S3, S4**). Spectra were
24 recorded at 50 nm/min scanning speed and a data pitch of 0.2 nm. Four scans were averaged to
25 obtain the final spectra. The contribution of the buffer was subtracted and spectra were normalized
26 by peptide bond concentration. We considered that major changes in the shape of the CD spectrum
27 that cannot be explained by concentration inaccuracies are a signature of strong domain
28 destabilization. To study thermal denaturation, CD signal at a wavelength at which folded and
29 unfolded protein signals were different was monitored as temperature increased from 25 to 85°C
30 at a rate of $30^\circ\text{C}/\text{h}$ (**Supplementary File S4**). Temperature control was achieved using a Peltier
31 thermoelectric system. Changes in CD signal were fit to a sigmoidal function using IGOR Pro
32 (Wavemetrics) to estimate T_m .

33

34 **Molecular Dynamics simulations**

35 Full atom MD simulations of the C1, C3, C4, C5, C9 and C10 cMyBP-C domains (WT and their
36 variants, see **Supplementary Table S3**) in dodecahedral boxes (1 nm minimal distance between
37 protein atoms and box edges) filled with Tip3p water molecules were performed at 410 K in
38 protonation conditions mimicking pH 7.0 using the Charmm27+CMAP force field as described
39 ⁷². In the absence of high-resolution structures, we resorted to homology models obtained using
40 SwissModel ⁷³. Mutations were modelled on the WT structures using SwissPdbViewer v4.1.0 ⁷³.
41 For each WT and variant structure, three 1- μs long trajectories were obtained. Trajectories were
42 analyzed using the model described in ⁷⁴ to obtain estimations of $\Delta\Delta G$ upon mutation at 298 K.

43

44 **Supplementary Information** is available in the online version of the article. Supplementary info
45 includes 4 independent Supplementary Files, 8 Supplementary Figures, 2 Supplementary Notes,
46 3 Supplementary Tables and Supplementary References.

47

1 **Acknowledgements**

2 JAC acknowledges funding from the *Ministerio de Ciencia e Innovación* (MCIN) through grants
3 BIO2014-54768-P, BIO2017-83640-P (AEI/FEDER, UE), EIN2019-102966 and RYC-2014-
4 16604, the European Research Area Network on Cardiovascular Diseases (ERA-CVD/ISCIII,
5 MINOTAUR, AC16/00045) and the *Comunidad de Madrid* (consortium Tec4Bio-CM,
6 S2018/NMT-4443, FEDER). The CNIC is supported by the *Instituto de Salud Carlos III* (ISCIII),
7 MCIN and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-
8 0505). We acknowledge funding from ISCIII to the *Centro de Investigación Biomédica en Red*
9 (CIBERCV), CB16/11/00425. LS acknowledges funding from MCIN (BFU2015-63571-P). JS
10 acknowledges funding from MCIN (BFU2016-78232-P), Gobierno de Aragón (E45_17R) and
11 ERDF-InterregV-A POCTEFA (PIREPRED-EFA086/15). CSC is the recipient of an FPI-SO
12 predoctoral fellowship BES-2016-076638. MRP was the recipient of a PhD fellowship from the
13 Italian Ministry of Education, Universities and Research (MIUR). HGC is recipient of the
14 FPU16/04232 doctoral contract from MCIN. We thank Natalia Vicente for excellent technical
15 support (through grant PEJ16/MED/TL-1593 from *Consejería de Educación, Juventud y Deporte*
16 *de la Comunidad de Madrid* and the European Social Fund). We thank the Spectroscopy and
17 Nuclear Magnetic Resonance Core Unit at CNIO for access to CD instrumentation. We thank
18 Andrea Thompson and Sharlene Day for critical reading of the manuscript. We thank all members
19 of the *Molecular Mechanics of the Cardiovascular System* team for helpful discussions and four
20 anonymous reviewers for constructive feedback.

21

22 **Author contributions**

23 JAC conceived the project. DGG, PGP, MRP, JAC and LM classified genetic variants according
24 to pathogenicity. MRP and JAC did bioinformatics analysis of RNA splicing. JD, JAC and LS
25 predicted changes in protein stability. DSO, SV, FD, JRG, MSM, RBV, GF, PGP and JAC
26 ensured procurement of human samples. MRP and CSC did experimental analysis of RNA
27 splicing. CSC and DVC cloned and purified proteins. CSC and EHG did circular dichroism
28 experiments. JJGF, HGC and JS did molecular dynamics simulations. CSC, MRP and JAC
29 drafted the manuscript with input from all authors.

30

31 **Competing financial interests**

32 LM is share-holder of Health in Code.

1 REFERENCES

- 2 1 Braunwald, E. in *Hypertrophic Cardiomyopathy* (ed S.S. Naidu) Ch. 1, 1-8 (Springer,
3 2015).
- 4 2 Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the
5 prevalence of hypertrophic cardiomyopathy. *Journal of the American College of*
6 *Cardiology* **65**, 1249-1254 (2015). <<http://www.ncbi.nlm.nih.gov/pubmed/25814232>>.
- 7 3 Alcalai, R., Seidman, J. G. & Seidman, C. E. Genetic basis of hypertrophic
8 cardiomyopathy: from bench to the clinics. *Journal of cardiovascular electrophysiology*
9 **19**, 104-110 (2008). <<http://www.ncbi.nlm.nih.gov/pubmed/17916152>>.
- 10 4 Semsarian, C. & Ingles, J. in *Hypertrophic Cardiomyopathy* (ed S.S. Naidu) (Springer-
11 Verlag, 2015).
- 12 5 MacArthur, D. G., Manolio, T. A., Dimmock, D. P., Rehm, H. L., Shendure, J., Abecasis,
13 G. R., . . . Gunter, C. Guidelines for investigating causality of sequence variants in
14 human disease. *Nature* **508**, 469-476 (2014).
15 <<https://www.ncbi.nlm.nih.gov/pubmed/24759409>>.
- 16 6 Jordan, D. M., Kiezun, A., Baxter, S. M., Agarwala, V., Green, R. C., Murray, M. F., . . .
17 Sunyaev, S. R. Development and Validation of a Computational Method for
18 Assessment of Missense Variants in Hypertrophic Cardiomyopathy. *The American*
19 *Journal of Human Genetics* **88**, 183-192 (2011).
20 <<http://www.sciencedirect.com/science/article/pii/S0002929711000127>>.
- 21 7 Ito, K., Patel, P. N., Gorham, J. M., McDonough, B., DePalma, S. R., Adler, E. E., . . .
22 Seidman, J. G. Identification of pathogenic gene mutations in LMNA and MYBPC3 that
23 alter RNA splicing. *Proceedings of the National Academy of Sciences of the United*
24 *States of America* **114**, 7689-7694 (2017).
25 <<http://www.ncbi.nlm.nih.gov/pubmed/28679633>>.
- 26 8 Singer, E. S., Ingles, J., Semsarian, C. & Bagnall, R. D. Key Value of RNA Analysis of
27 MYBPC3 Splice-Site Variants in Hypertrophic Cardiomyopathy. *Circ Genom Precis Med*
28 **12**, e002368 (2019). <<https://www.ncbi.nlm.nih.gov/pubmed/30645170>>.
- 29 9 Lv, W., Qiao, L., Petrenko, N., Li, W., Owens Anjali, T., McDermott-Roe, C. & Musunuru,
30 K. Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-
31 Edited Cardiomyocytes. *Circulation* **138**, 2852-2854 (2018).
32 <<https://doi.org/10.1161/CIRCULATIONAHA.118.035028>>.
- 33 10 Walsh, R., Mazzarotto, F., Whiffin, N., Buchan, R., Midwinter, W., Wilk, A., . . . Ware, J.
34 S. Quantitative approaches to variant classification increase the yield and precision of
35 genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy.
36 *Genome Med* **11**, 5 (2019). <<https://www.ncbi.nlm.nih.gov/pubmed/30696458>>.
- 37 11 Sadayappan, S. & de Tombe, P. P. Cardiac myosin binding protein-C as a central target
38 of cardiac sarcomere signaling: a special mini review series. *Pflugers Arch* **466**, 195-200
39 (2014). <<http://www.ncbi.nlm.nih.gov/pubmed/24196566>>.
- 40 12 Yotti, R., Seidman, C. E. & Seidman, J. G. Advances in the Genetic Basis and
41 Pathogenesis of Sarcomere Cardiomyopathies. *Annu Rev Genomics Hum Genet* **20**,
42 129-153 (2019). <<https://www.ncbi.nlm.nih.gov/pubmed/30978303>>.
- 43 13 Walsh, R., Thomson, K. L., Ware, J. S., Funke, B. H., Woodley, J., McGuire, K. J., . . .
44 Watkins, H. Reassessment of Mendelian gene pathogenicity using 7,855
45 cardiomyopathy cases and 60,706 reference samples. *Genet Med* **19**, 192-203 (2017).
46 <<https://www.ncbi.nlm.nih.gov/pubmed/27532257>>.
- 47 14 Harris, S. P., Lyons, R. G. & Bezold, K. L. In the thick of it: HCM-causing mutations in
48 myosin binding proteins of the thick filament. *Circ Res* **108**, 751-764 (2011).
49 <<http://www.ncbi.nlm.nih.gov/pubmed/21415409>>.
- 50 15 van Dijk, S. J., Dooijes, D., dos Remedios, C., Michels, M., Lamers, J. M., Winegrad, S., . . .
51 . van der Velden, J. Cardiac myosin-binding protein C mutations and hypertrophic

- 1 cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte
2 dysfunction. *Circulation* **119**, 1473-1483 (2009).
3 <http://www.ncbi.nlm.nih.gov/pubmed/19273718>.
- 4 16 Marston, S., Copeland, O., Gehmlich, K., Schlossarek, S. & Carrier, L. How do MYBPC3
5 mutations cause hypertrophic cardiomyopathy? *Journal of muscle research and cell*
6 *motility* **33**, 75-80 (2012). <http://www.ncbi.nlm.nih.gov/pubmed/22057632>.
- 7 17 Toepfer, C. N., Wakimoto, H., Garfinkel, A. C., McDonough, B., Liao, D., Jiang, J., . . .
8 Seidman, C. E. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate
9 myosin. *Sci Transl Med* **11** (2019).
10 <https://www.ncbi.nlm.nih.gov/pubmed/30674652>.
- 11 18 Helms, A. S., Davis, F. M., Coleman, D., Bartolone, S. N., Glazier, A. A., Pagani, F., . . .
12 Day, S. M. Sarcomere mutation-specific expression patterns in human hypertrophic
13 cardiomyopathy. *Circulation. Cardiovascular genetics* **7**, 434-443 (2014).
14 <http://www.ncbi.nlm.nih.gov/pubmed/25031304>.
- 15 19 Page, S. P., Kounas, S., Syrris, P., Christiansen, M., Frank-Hansen, R., Andersen, P. S., . . .
16 McKenna, W. J. Cardiac myosin binding protein-C mutations in families with
17 hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long
18 term outcome. *Circulation. Cardiovascular genetics* **5**, 156-166 (2012).
19 <http://www.ncbi.nlm.nih.gov/pubmed/22267749>.
- 20 20 Erdmann, J., Raible, J., Maki-Abadi, J., Hummel, M., Hammann, J., Wollnik, B., . . .
21 Regitz-Zagrosek, V. Spectrum of clinical phenotypes and gene variants in cardiac
22 myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. *Journal*
23 *of the American College of Cardiology* **38**, 322-330 (2001).
24 <http://www.ncbi.nlm.nih.gov/pubmed/11499719>.
- 25 21 Xiong, H. Y., Alipanahi, B., Lee, L. J., Bretschneider, H., Merico, D., Yuen, R. K. C., . . .
26 Frey, B. J. The human splicing code reveals new insights into the genetic determinants
27 of disease. *Science* **347** (2015).
28 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362528/>.
- 29 22 Yue, P., Li, Z. & Moulton, J. Loss of protein structure stability as a major causative factor
30 in monogenic disease. *Journal of molecular biology* **353**, 459-473 (2005).
31 <http://www.ncbi.nlm.nih.gov/pubmed/16169011>.
- 32 23 Ababou, A., Rostkova, E., Mistry, S., Le Masurier, C., Gautel, M. & Pfuhl, M. Myosin
33 binding protein C positioned to play a key role in regulation of muscle contraction:
34 structure and interactions of domain C1. *Journal of molecular biology* **384**, 615-630
35 (2008). <https://www.ncbi.nlm.nih.gov/pubmed/18926831>.
- 36 24 Smelter, D. F., Lange, W. J. d., Cai, W., Ge, Y. & Ralphe, J. C. The HCM-linked W792R
37 mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
38 *American Journal of Physiology-Heart and Circulatory Physiology* **314**, H1179-H1191
39 (2018). <https://www.physiology.org/doi/abs/10.1152/ajpheart.00686.2017>.
- 40 25 van Dijk, S. J., Bezold Kooiker, K., Mazzalupo, S., Yang, Y., Kostyukova, A. S., Mustacich,
41 D. J., . . . Harris, S. P. The A31P missense mutation in cardiac myosin binding protein C
42 alters protein structure but does not cause haploinsufficiency. *Archives of biochemistry*
43 *and biophysics* **601**, 133-140 (2016).
44 <http://www.ncbi.nlm.nih.gov/pubmed/26777460>.
- 45 26 Pricolo, M. R., Herrero-Galán, E., Mazzaccara, C., Losi, M. A., Alegre-Cebollada, J. &
46 Frisso, G. Protein Thermodynamic Destabilization in the Assessment of Pathogenicity
47 of a Variant of Uncertain Significance in Cardiac Myosin Binding Protein C. *Journal of*
48 *Cardiovascular Translational Research* (2020). [https://doi.org/10.1007/s12265-020-](https://doi.org/10.1007/s12265-020-09959-6)
49 [09959-6](https://doi.org/10.1007/s12265-020-09959-6).
- 50 27 Kobayashi, Y., Yang, S., Nykamp, K., Garcia, J., Lincoln, S. E. & Topper, S. E. J. G. M.
51 Pathogenic variant burden in the ExAC database: an empirical approach to evaluating

- 1 population data for clinical variant interpretation. *Genome Med* **9**, 13 (2017).
2 <https://doi.org/10.1186/s13073-017-0403-7>.
- 3 28 Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., . . . Rehm, H. L.
4 Standards and guidelines for the interpretation of sequence variants: a joint consensus
5 recommendation of the American College of Medical Genetics and Genomics and the
6 Association for Molecular Pathology. *Genetics In Medicine* **17**, 405 (2015).
7 <https://doi.org/10.1038/gim.2015.30>.
- 8 29 Lee, Y. & Rio, D. C. Mechanisms and Regulation of Alternative Pre-mRNA Splicing.
9 *Annual Review of Biochemistry* **84**, 291-323 (2015). [https://doi.org/10.1146/annurev-](https://doi.org/10.1146/annurev-biochem-060614-034316)
10 [biochem-060614-034316](https://doi.org/10.1146/annurev-biochem-060614-034316).
- 11 30 Carrier, L., Bonne, G., Barend, E., Yu, B., Richard, P., Niel, F., . . . Schwartz, K.
12 Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3)
13 and identification of mutations predicted to produce truncated proteins in familial
14 hypertrophic cardiomyopathy. *Circ Res* **80**, 427-434 (1997).
15 <http://www.ncbi.nlm.nih.gov/pubmed/9048664>.
- 16 31 Bonne, G., Carrier, L., Bercovici, J., Cruaud, C., Richard, P., Hainque, B., . . . Schwartz, K.
17 Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with
18 familial hypertrophic cardiomyopathy. *Nature genetics* **11**, 438-440 (1995).
19 <http://www.ncbi.nlm.nih.gov/pubmed/7493026>.
- 20 32 Rottbauer, W., Gautel, M., Zehelein, J., Labeit, S., Franz, W. M., Fischer, C., . . . Katus,
21 H. A. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in
22 familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and
23 protein. *The Journal of clinical investigation* **100**, 475-482 (1997).
24 <http://www.ncbi.nlm.nih.gov/pubmed/9218526>.
- 25 33 Bagnall, R. D., Ingles, J., Dinger, M. E., Cowley, M. J., Ross, S. B., Minoche, A. E., . . .
26 Semsarian, C. Whole Genome Sequencing Improves Outcomes of Genetic Testing in
27 Patients With Hypertrophic Cardiomyopathy. *Journal of the American College of*
28 *Cardiology* **72**, 419-429 (2018). <https://www.ncbi.nlm.nih.gov/pubmed/30025578>.
- 29 34 Frisso, G., Detta, N., Coppola, P., Mazzaccara, C., Pricolo, M. R., D'Onofrio, A., . . .
30 Salvatore, F. Functional Studies and In Silico Analyses to Evaluate Non-Coding Variants
31 in Inherited Cardiomyopathies. *Int J Mol Sci* **17** (2016).
32 <https://www.ncbi.nlm.nih.gov/pubmed/27834932>.
- 33 35 Frisso, G., Limongelli, G., Pacileo, G., Del Giudice, A., Forgione, L., Calabrò, P., . . .
34 Salvatore, F. A child cohort study from southern Italy enlarges the genetic spectrum of
35 hypertrophic cardiomyopathy. *Clinical Genetics* **76**, 91-101 (2009).
36 <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-0004.2009.01190.x>.
- 37 36 Crehalet, H., Millat, G., Albuissou, J., Bonnet, V., Rouvet, I., Rousson, R. & Bozon, D.
38 Combined use of in silico and in vitro splicing assays for interpretation of genomic
39 variants of unknown significance in cardiomyopathies and channelopathies. *2012* **2**
40 (2012). <https://www.pagepressjournals.org/index.php/cardiogen/article/view/423>.
- 41 37 Andersen, P. S., Havndrup, O., Bundgaard, H., Larsen, L. A., Vuust, J., Pedersen, A. K., . . .
42 Christiansen, M. Genetic and phenotypic characterization of mutations in myosin-
43 binding protein C (MYBPC3) in 81 families with familial hypertrophic cardiomyopathy:
44 total or partial haploinsufficiency. *Eur J Hum Genet* **12**, 673-677 (2004).
45 <https://www.ncbi.nlm.nih.gov/pubmed/15114369>.
- 46 38 Höhfeld, J., Cyr, D. M. & Patterson, C. From the cradle to the grave: molecular
47 chaperones that may choose between folding and degradation. *EMBO reports* **2**, 885-
48 890 (2001). <http://embor.embopress.org/content/embor/2/10/885.full.pdf>.
- 49 39 Guerois, R., Nielsen, J. E. & Serrano, L. Predicting changes in the stability of proteins
50 and protein complexes: a study of more than 1000 mutations. *Journal of molecular*
51 *biology* **320**, 369-387 (2002). <http://www.ncbi.nlm.nih.gov/pubmed/12079393>.

- 1 40 Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E.
2 C. & Ferrin, T. E. UCSF Chimera--a visualization system for exploratory research and
3 analysis. *J Comput Chem* **25**, 1605-1612 (2004).
4 <<https://www.ncbi.nlm.nih.gov/pubmed/15264254>>.
- 5 41 Kelly, S. M. & Price, N. C. The use of circular dichroism in the investigation of protein
6 structure and function. *Current protein & peptide science* **1**, 349-384 (2000).
7 <<http://www.ncbi.nlm.nih.gov/pubmed/12369905>>.
- 8 42 Greenfield, N. J. Using circular dichroism collected as a function of temperature to
9 determine the thermodynamics of protein unfolding and binding interactions. *Nat*
10 *Protoc* **1**, 2527-2535 (2006). <<https://www.ncbi.nlm.nih.gov/pubmed/17406506>>.
- 11 43 Zhang, X. L., De, S., McIntosh, L. P. & Paetzel, M. Structural characterization of the C3
12 domain of cardiac myosin binding protein C and its hypertrophic cardiomyopathy-
13 related R502W mutant. *Biochemistry* **53**, 5332-5342 (2014).
14 <<http://www.ncbi.nlm.nih.gov/pubmed/25058872>>.
- 15 44 Allali-Hassani, A., Wasney, Gregory A., Chau, I., Hong, Bum S., Senisterra, G., Loppnau,
16 P., . . . Vedadi, M. A survey of proteins encoded by non-synonymous single nucleotide
17 polymorphisms reveals a significant fraction with altered stability and activity.
18 *Biochemical Journal* **424**, 15-26 (2009). <<https://doi.org/10.1042/BJ20090723>>.
- 19 45 Maron, B. J., Maron, M. S. & Semsarian, C. Genetics of hypertrophic cardiomyopathy
20 after 20 years: clinical perspectives. *Journal of the American College of Cardiology* **60**,
21 705-715 (2012). <<http://www.ncbi.nlm.nih.gov/pubmed/22796258>>.
- 22 46 D'Argenio, V., Frisso, G., Precone, V., Boccia, A., Fienga, A., Pacileo, G., . . . Salvatore, F.
23 DNA Sequence Capture and Next-Generation Sequencing for the Molecular Diagnosis
24 of Genetic Cardiomyopathies. *The Journal of Molecular Diagnostics* **16**, 32-44 (2014).
25 <<http://www.sciencedirect.com/science/article/pii/S1525157813002122>>.
- 26 47 Lappalainen, T., Scott, A. J., Brandt, M. & Hall, I. M. Genomic Analysis in the Age of
27 Human Genome Sequencing. *Cell* **177**, 70-84 (2019).
28 <<https://www.ncbi.nlm.nih.gov/pubmed/30901550>>.
- 29 48 Homburger, J. R., Green, E. M., Caleshu, C., Sunitha, M. S., Taylor, R. E., Ruppel, K. M., .
30 . . Ashley, E. A. Multidimensional structure-function relationships in human beta-
31 cardiac myosin from population-scale genetic variation. *Proceedings of the National*
32 *Academy of Sciences of the United States of America* **113**, 6701-6706 (2016).
33 <<http://www.ncbi.nlm.nih.gov/pubmed/27247418>>.
- 34 49 McNally, E. M. & George, A. L. New approaches to establish genetic causality. *Trends in*
35 *Cardiovascular Medicine* **25**, 646-652 (2015).
36 <<http://www.sciencedirect.com/science/article/pii/S105017381500064X>>.
- 37 50 Ashley, E. A., Reuter, C. M. & Wheeler, M. T. Genome Sequencing in
38 Hypertrophic Cardiomyopathy. **72**, 430-433 (2018).
39 <<http://www.onlinejacc.org/content/accj/72/4/430.full.pdf>>.
- 40 51 Rosano, G. L. & Ceccarelli, E. A. Recombinant protein expression in *Escherichia coli*:
41 advances and challenges. *Front Microbiol* **5**, 172 (2014).
42 <<https://www.ncbi.nlm.nih.gov/pubmed/24860555>>.
- 43 52 Porebski, B. T., Nickson, A. A., Hoke, D. E., Hunter, M. R., Zhu, L., McGowan, S., . . .
44 Buckle, A. M. Structural and dynamic properties that govern the stability of an
45 engineered fibronectin type III domain. *Protein Engineering, Design and Selection* **28**,
46 67-78 (2015). <<https://doi.org/10.1093/protein/gzv002>>.
- 47 53 Pfuhl, M. & Gautel, M. Structure, interactions and function of the N-terminus of
48 cardiac myosin binding protein C (MyBP-C): who does what, with what, and to whom?
49 *Journal of muscle research and cell motility* **33**, 83-94 (2012).
50 <<http://www.ncbi.nlm.nih.gov/pubmed/22527637>>.
- 51 54 Marston, S., Copeland, O., Jacques, A., Livesey, K., Tsang, V., McKenna, W. J., . . .
52 Watkins, H. Evidence from human myectomy samples that MYBPC3 mutations cause

- 1 hypertrophic cardiomyopathy through haploinsufficiency. *Circ Res* **105**, 219-222
2 (2009). <<http://www.ncbi.nlm.nih.gov/pubmed/19574547>>.
- 3 55 Vignier, N., Schlossarek, S., Fraysse, B., Mearini, G., Kramer, E., Pointu, H., . . . Carrier,
4 L. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac
5 myosin-binding protein C mutant levels in cardiomyopathic mice. *Circ Res* **105**, 239-
6 248 (2009). <<http://www.ncbi.nlm.nih.gov/pubmed/19590044>>.
- 7 56 Bali, V. & Bebok, Z. Decoding mechanisms by which silent codon changes influence
8 protein biogenesis and function. *The International Journal of Biochemistry & Cell*
9 *Biology* **64**, 58-74 (2015).
10 <<http://www.sciencedirect.com/science/article/pii/S1357272515000801>>.
- 11 57 Scheper, G. C., van der Knaap, M. S. & Proud, C. G. Translation matters: protein
12 synthesis defects in inherited disease. *Nature Reviews Genetics* **8**, 711 (2007).
13 <<https://doi.org/10.1038/nrg2142>>.
- 14 58 Helms, A. S., Tang, V. T., O'Leary, T. S., Friedline, S., Wauchope, M., Arora, A., . . . Day,
15 S. M. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic
16 cardiomyopathy. *JCI insight* **5** (2020).
17 <<https://www.ncbi.nlm.nih.gov/pubmed/31877118>>.
- 18 59 Ravid, T. & Hochstrasser, M. Diversity of degradation signals in the ubiquitin-
19 proteasome system. *Nature Reviews Molecular Cell Biology* **9**, 679 (2008).
20 <<https://doi.org/10.1038/nrm2468>>.
- 21 60 Glazier, A. A., Hafeez, N., Mellacheruvu, D., Basrur, V., Nesvizhskii, A. I., Lee, L. M., . . .
22 Day, S. M. HSC70 is a chaperone for wild-type and mutant cardiac myosin binding
23 protein C. *JCI insight* **3** (2018). <<http://www.ncbi.nlm.nih.gov/pubmed/29875314>>.
- 24 61 Redwood, C. S., Watkins, H. & Moolman-Smook, J. C. Properties of mutant contractile
25 proteins that cause hypertrophic cardiomyopathy. *Cardiovascular research* **44**, 20-36
26 (1999). <[https://doi.org/10.1016/S0008-6363\(99\)00213-8](https://doi.org/10.1016/S0008-6363(99)00213-8)>.
- 27 62 Da'as, S. I., Fakhro, K., Thanassoulas, A., Krishnamoorthy, N., Saleh, A., Calver, B. L., . . .
28 Nomikos, M. Hypertrophic cardiomyopathy-linked variants of cardiac myosin binding
29 protein C3 display altered molecular properties and actin interaction. (2018).
30 <<http://www.biochemj.org/content/ppbiochemj/early/2018/11/16/BCJ20180685.full.pdf>>.
- 31 63 Bezold, K. L., Shaffer, J. F., Khosa, J. K., Hoye, E. R. & Harris, S. P. A gain-of-function
32 mutation in the M-domain of cardiac myosin-binding protein-C increases binding to
33 actin. *J Biol Chem* **288**, 21496-21505 (2013).
34 <<https://www.ncbi.nlm.nih.gov/pubmed/23782699>>.
- 35 64 Ababou, A., Gautel, M. & Pfuhl, M. Dissecting the N-terminal myosin binding site of
36 human cardiac myosin-binding protein C. Structure and myosin binding of domain C2.
37 *The Journal of biological chemistry* **282**, 9204-9215 (2007).
38 <<http://www.ncbi.nlm.nih.gov/pubmed/17192269>>.
- 39 65 Moolman-Smook, J., Flashman, E., de Lange, W., Li, Z., Corfield, V., Redwood, C. &
40 Watkins, H. Identification of novel interactions between domains of Myosin binding
41 protein-C that are modulated by hypertrophic cardiomyopathy missense mutations.
42 *Circ Res* **91**, 704-711 (2002). <<http://www.ncbi.nlm.nih.gov/pubmed/12386147>>.
- 43 66 Doh, C. Y., Li, J., Mamidi, R. & Stelzer, J. E. The HCM-causing Y235S cMyBPC mutation
44 accelerates contractile function by altering C1 domain structure. *Biochim Biophys Acta*
45 *Mol Basis Dis* **1865**, 661-677 (2019).
46 <<https://www.ncbi.nlm.nih.gov/pubmed/30611859>>.
- 47 67 McNamara, J. W., Li, A., Lal, S., Bos, J. M., Harris, S. P., van der Velden, J., . . . dos
48 Remedios, C. G. MYBPC3 mutations are associated with a reduced super-relaxed state
49 in patients with hypertrophic cardiomyopathy. *PLOS ONE* **12**, e0180064 (2017).
50 <<https://doi.org/10.1371/journal.pone.0180064>>.
- 51

- 1 68 van der Velden, J., Ho, C. Y., Tardiff, J. C., Olivotto, I., Knollmann, B. C. & Carrier, L.
2 Research priorities in sarcomeric cardiomyopathies. *Cardiovascular research* **105**, 449-
3 456 (2015). <<http://www.ncbi.nlm.nih.gov/pubmed/25631582>>.
- 4 69 Houdayer, C., Caux-Moncoutier, V., Krieger, S., Barrois, M., Bonnet, F., Bourdon, V., . . .
5 Stoppa-Lyonnet, D. Guidelines for splicing analysis in molecular diagnosis derived from
6 a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. **33**,
7 1228-1238 (2012). <<https://onlinelibrary.wiley.com/doi/abs/10.1002/humu.22101>>.
- 8 70 Amato, F., Bellia, C., Cardillo, G., Castaldo, G., Ciaccio, M., Elce, A., . . . Tomaiuolo, R.
9 Extensive Molecular Analysis of Patients Bearing CFTR-Related Disorders. *The Journal*
10 *of molecular diagnostics : JMD* **14**, 81-89 (2012).
- 11 71 Pimenta-Lopes, C., Suay-Corredera, C., Velázquez-Carreras, D., Sánchez-Ortiz, D. &
12 Alegre-Cebollada, J. Concurrent atomic force spectroscopy. *Communications Physics* **2**,
13 91 (2019). <<https://doi.org/10.1038/s42005-019-0192-y>>.
- 14 72 Galano-Frutos, J. J. & Sancho, J. Accurate Calculation of Barnase and SNase Folding
15 Energetics Using Short Molecular Dynamics Simulations and an Atomistic Model of the
16 Unfolded Ensemble: Evaluation of Force Fields and Water Models. *Journal of Chemical*
17 *Information and Modeling* **59**, 4350-4360 (2019).
18 <<https://doi.org/10.1021/acs.jcim.9b00430>>.
- 19 73 Guex, N., Peitsch, M. C. & Schwede, T. Automated comparative protein structure
20 modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective.
21 *ELECTROPHORESIS* **30**, S162-S173 (2009). <<https://doi.org/10.1002/elps.200900140>>.
- 22 74 Galano-Frutos, J. J., García-Cebollada, H. & Sancho, J. Molecular dynamics simulations
23 for genetic interpretation in protein coding regions: where we are, where to go and
24 when. *Briefings in Bioinformatics* (2019). <<https://doi.org/10.1093/bib/bbz146>>.

25